Physician profile
David Axelrod
NPI 1477574820
$64,695.61
in general payments reported to CMS, 2019-2025
10 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,250 · 2020: $11K · 2022: $45.57 · 2023: $175 · 2024: $32K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Travel and Lodging: $7,326 · Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,093.33 |
| Travel and Lodging | $7,326.06 |
| Food and Beverage | $809.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $26,151.22 | 2024 | Ultomiris |
| Bridge To Life Ltd | $18,300.35 | 2024-2025 | |
| Genzyme Corporation | $11,170.73 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $8,250.00 | 2019 | |
| Zoll Medical Corporation | $393.33 | 2024 | Defibrillator |
| Current Health, INC. | $175.00 | 2023 | |
| Sanofi-Aventis U.S. LLC | $160.77 | 2022-2025 | |
| Ethicon US, LLC | $46.62 | 2025 | Echelon; Endopath, Surgiflo Hemostatic Matrix, Ethicon |
| Conmed Corporation | $25.30 | 2024 | Airseal |
| Merck Sharp & Dohme LLC | $22.29 | 2025 | Zerbaxa, Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Axelrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.